On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the November 2022 CRG meeting.
Actions in this consultation include:
- Ozanimod for moderately to severely active ulcerative colitis – RED
- Relugolix / estradiol / norethisterone for moderate to severe symptoms of uterine fibroids – GREEN (following specialist advice)
- Remove fostamatinib from DNP list and assign a RED status
- Replace links to superseded NICE clinical guideline CG177 with links to NG226: Osteroarthritis in over 16s. Formulary note regarding glucosamine updated to read “Do not offer glucosamine products or strong opioids for the management of osteoarthritis.”
All links to MHRA drug safety updates will be added to formulary as appropriate.
To take part in this consultation, visit the consultations page. The consultation period is open until 5pm on Friday 23rd December 2022.